Browse studies

Find your next paid study

26 recruiting studies matching your filters

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to N…

NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Akero Therapeutics, IncNCT06528314

Phase 1

A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)

This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom…

MASH - Metabolic Dysfunction-Associated SteatohepatitisHeart Failure With Preserved Ejection Fraction (HFPEF)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Madrigal Pharmaceuticals, Inc.NCT07830758

AGED Diagnostics Clinical Research Study to Validate Liver Disease and Metabolic Associated Disease Biomarkers

Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate t…

MASH - Metabolic Dysfunction-Associated SteatohepatitisMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)Fibrosis and Cirrhosis of Liver+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Active Genomes Expressed Diagnostics, CorpNCT07867574

Phase 4

Assessing Nutrition-aligned Resmetirom Roll-out

This randomized control trial aims to evaluate the effectiveness of combining resmetirom therapy (first approved pharmacological therapy for treating metabolic…

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$25 – $1,000

Actual pay is set by the research site.

City University of New YorkNCT07680478

Observational

Feasibility Study of Time Restricted Eating and a Healthy Diet in Patients Receiving Liver-Directed Therapy for Hepatocellular Carcinoma

This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll a…

Liver Cancer, AdultMASH - Metabolic Dysfunction-Associated SteatohepatitisObesity and Overweight

Estimated

~$10 – $750

Actual pay is set by the research site.

University of California, San DiegoNCT06824974

Phase 3

A Phase 3, Two-part, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis (Stage F4 Fibrosis) Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-2)

This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with co…

Metabolic Dysfunction-associated Steatohepatitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

GlaxoSmithKlineNCT07704892

Phase 2

A Parallel Treatment Group, Phase 2a, Double-blind, 4-arm Trial to Evaluate the Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Male and Female Participants Aged 30 Years or Older With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with …

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Rivus Pharmaceuticals, Inc.NCT07491458

Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfuncti…

Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT05519475

Phase 3

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and…

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Altimmune, Inc.NCT07795164

Phase 2

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and …

Metabolic Dysfunction-associated Steatohepatitis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

EccogeneNCT07288138

MASH/MetALD Consortium for the Assessment of Non-Invasive Testing in Monitoring Interventions, Treatment Response, and Major Liver-Related Outcomes

This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction…

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMASLDMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease+2 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

HRI-MAIL-NITNCT06986447

Phase 2

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabol…

Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease

Estimated

~$75 – $3,000

Actual pay is set by the research site.

GlaxoSmithKlineNCT06920043